Pharmaceutical

MEDI-0618 by AstraZeneca for Migraine: Likelihood of Approval

MEDI-0618 is under clinical development by AstraZeneca and currently in Phase I for Migraine.

Jun 18, 2024 - 04:00
MEDI-0618 is under clinical development by AstraZeneca and currently in Phase I for Migraine.
Read the original article

Tags:

Previous Article

OCT-461201 by Oxford Cannabinoid Technologies for Neuropathic Pain (Neuralgia): ...

Next Article

DFV-890 by Novartis for Coronary Artery Disease (CAD) (Ischemic Heart Disease): ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Biotech executive nominated to Biogen board is mother of director’s child, records show

STAT+: Biotech executive nominated to Biogen board is m...

Jun 14, 2023

STAT+: Study on Amgen’s ‘bispecific’ immunotherapy could lead to approval in small cell lung cancer

STAT+: Study on Amgen’s ‘bispecific’ immunotherapy coul...

Oct 20, 2023

AFM-24I by Affimed for Metastatic Hepatocellular Carcin...

Feb 8, 2024